Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Our Products – TG |
Description | Fiercely Focused On BRIUMVI ® (ublituximab-xiiy) IS NOW APPROVED. PRESCRIBING INFORMATION ABOUT US Our Story Message From Our CEO Leadership Team Board Members Guiding Princi |
Keywords | N/A |
WebSite | ukoniq.com |
Host IP | 155.130.138.30 |
Location | United States |
Site | Rank |
US$1,911
Last updated: 2023-05-11 11:41:25
ukoniq.com has Semrush global rank of 0. ukoniq.com has an estimated worth of US$ 1,911, based on its estimated Ads revenue. ukoniq.com receives approximately 220 unique visitors each day. Its web server is located in United States, with IP address 155.130.138.30. According to SiteAdvisor, ukoniq.com is safe to visit. |
Purchase/Sale Value | US$1,911 |
Daily Ads Revenue | US$1 |
Monthly Ads Revenue | US$52 |
Yearly Ads Revenue | US$635 |
Daily Unique Visitors | 14 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
ukoniq.com. | A | 599 | IP: 155.130.138.30 |
ukoniq.com. | NS | 3600 | NS Record: pdns07.domaincontrol.com. |
ukoniq.com. | NS | 3600 | NS Record: pdns08.domaincontrol.com. |
BRIUMVI ® (ublituximab-xiiy) IS NOW APPROVED. PRESCRIBING INFORMATION ABOUT US Our Story Message From Our CEO Leadership Team Board Members Guiding Principles Join Us OUR SCIENCE Our Approach Our Focus MZL/FL CLL MS Collaborate With Us Meet with TG Medical OUR PRODUCTS OUR PIPELINE Overview Umbralisib Ublituximab TG-1501 TG-1701 TG 1801 OUR PUBLICATIONS OUR TRIALS Trial Information Expanded Access Policy INVESTORS & MEDIA Press Releases Stock Information Historic Stock Lookup Sec Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Leadership Team Corporate Governance Faqs Mobile Menu Mobile Close ABOUT US Our Story Message From Our CEO Leadership Team Board Members Guiding Principles Join Us OUR SCIENCE Our Approach Our Focus MZL/FL CLL MS Collaborate With Us Meet with TG Medical OUR PRODUCTS OUR PIPELINE Overview Umbralisib Ublituximab TG-1501 TG-1701 TG 1801 OUR PUBLICATIONS OUR TRIALS Trial Information Expanded Access Policy INVESTORS & MEDIA |
HTTP/1.1 301 Moved Permanently Server: nginx Date: Thu, 04 Nov 2021 16:33:41 GMT Content-Type: text/html Content-Length: 162 Connection: keep-alive Location: https://ukoniq.com/ HTTP/2 200 server: nginx date: Thu, 04 Nov 2021 16:33:41 GMT content-type: text/html content-length: 56292 x-accel-version: 0.01 last-modified: Fri, 02 Jul 2021 16:02:08 GMT etag: "dbe4-5c62613e20602" accept-ranges: bytes strict-transport-security: max-age=63072000; includeSubDomains x-powered-by: PleskLin |
Domain Name: UKONIQ.COM Registry Domain ID: 2452533768_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-12-19T15:13:15Z Creation Date: 2019-11-07T19:23:26Z Registry Expiry Date: 2022-11-07T19:23:26Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: PDNS07.DOMAINCONTROL.COM Name Server: PDNS08.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-22T08:34:58Z <<< |